Decision

Early access to medicines scheme (EAMS) scientific opinion: Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (HCV) infection in adults

This publication was withdrawn on

Withdrawn as this product received a marketing authorisation from the European Commission.

EAMS scientific opinion given to Glecaprevir/Pibrentasvir inclduing the public assessment report.